Neumora reports favorable NMRA-215 toxicology results
Neumora Therapeutics reported positive preclinical toxicology data for its NLRP3 inhibitor NMRA-215. The results support the advancement of the drug candidate to the clinic. The company plans to file its IND in late 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day